BioCentury
ARTICLE | Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

Nura aims to prevent axon degeneration, preserve neurons starting with an axon death switch

August 5, 2020 12:09 AM UTC

Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and reducing neuroinflammation. Led by Vir and Biogen veteran Alpna Seth, the South San Francisco company is developing a small molecule that inhibits SARM1, an axon death switch.

The Column Group, which founded Nura Bio Inc. in 2018, led the round with participation from Samsara BioCapital and Euclidean Capital. TCG’s Tim Kutzkey serves as chairman...

BCIQ Company Profiles

Nura Bio Inc.